Exhibit 99.2

INVESTOR PRESENTATION Frank Bedu-Addo Ph.D. President & CEO January 2022

2 This presentation contains forward-looking statements about PDS Biotechnology Corporation (“PDSB”), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre- clinical and clinical drug development activities and timelines and market opportunities. All statements other than statements of historical facts included in this presentation are forward-looking statements. The words “anticipates,” “may,” “can,” “plans,” “believes,” “estimates,” “expects,” “projects,” “intends,” “likely,” “will,” “should,” “to be,” and any similar expressions or other words of similar meaning are intended to identify those assertions as forward-looking statements. These forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that may cause actual results to differ materially from such forward-looking statements include those identified under the caption “Risk Factors” in the documents filed with the Securities and Exchange Commission (“SEC”) from time to time, including its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. Except to the extent required by applicable law or regulation, PDSB undertakes no obligation to update the forward-looking statements included in this presentation to reflect subsequent events or circumstances. Forward Looking Statements

Clinical-stage Company developing broad-based immunotherapies to treat cancer and infectious diseaseVersamune® and Infectimune™ platforms leverage the body’s own defense systems to prime antigen-specific killer T-cells and antibodies to combat cancer and infectious diseaseThree Phase 2 oncology clinical trials in progress with readouts anticipated Q1/Q2Preliminary data released at 2021 ASCO - Checkpoint inhibitor refractory patient survival exceeded alternative checkpoint inhibitor monotherapy treatmentClinical partnerships with Merck, MD Anderson Cancer Center and National Cancer InstituteDebt free with approximately $69.7M in cash as of September 30, 2021Recent updates for HPV Program (PDS0101) and Universal Flu (PDS0202) Corporate Overview 3

Versamune® Oncology Platform

5 Generate the right type and quantity of effective CD8+ killer T-cells Generate potency without serious systemic side effects Generate memory T-cells, to enhance durability of response Competitive Barrier to Entry:Versamune® is designed to promote powerful, CD8+ killer T-cell responses in vivo Versamune®-based therapies also show promising potential to: 70-90% of cancer patients fail check point inhibitor therapy 5

Versamune® is Designed to Recruit, Train and Arm T-cells in the Body 6 References: Gandhapudi SK, et al. 2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol. 202 (12): 3524-3536. Smalley Rumfield C et al. 2020. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J. for ImmunoTherapy of Cancer 8:e000612. 1. Recruits T-cells to lymph nodes 2. Trains T-cells to target tumors 3. Arms T-cells to kill tumor cells Versamune® + Tumor-associated proteins (antigens)

Strong Pipeline with Industry-Leading PartnershipsVersamune®-based oncology pipeline is being developed in partnership with the leaders in immuno-oncology 7 Reference: Data on file.

8 More than 40,500 patients were estimated to have been diagnosed last year with HPV16-associated cancers in the US1, 2HPV vaccination is not expected to impact the rate of HPV-related cancer incidence for decadesExisting immunotherapies cost $150,000+ annually per patient3 1SEER Research Data 1975-2018. 2Martel et al. 2017. International Journal of Cancer, Worldwide burden of cancer attributable to HPV by site, country and HPV type. 3Hernandez et al. 2018. American Journal of Managed Care Volume 24, Issue 2; Company Research US HPV-associated cancer incidence1, 2 Lead Asset PDS0101: Designed to treat human papillomavirus (HPV16)-associated cancers, representing a $6B opportunity in the US

9 Triple combination shows promising survival of patients with advanced refractory HPV16-associated cancers Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. As of 12/31/21: 37 patients (30 HPV16 positive) evaluatedApprox. 3:1 refractory to naïve patientsStudy progressing and recruiting; updates will be provided in the future Standard of Care Checkpoint Inhibitors Indications targeted in study – cervical, anal, head and neck, vaginal, penile

ASCO 2021: Interim proof-of-concept data suggests targeted CD8+ killer T-cell response induced by Versamune® results in tumor shrinkage 10 Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501. * These numbers reflect data as of evaluation of 25 patients; numbers will change as more patients undergo evaluation, includes both CPI refractory and naïve patients. 67% (12/18) 12% - 24% 0% (0/7)

11 Phase 2: PDS0101 + KEYTRUDA®Company-sponsored trial for the treatment of HPV16-positive metastatic/recurrent head and neck cancer (VERSATILE-002) Indication Treatment of patients with HPV16-positive head and neck cancer whose cancer has spread or returned Clinical Agents KEYTRUDA® (Standard of Care): Anti-PD1 checkpoint inhibitor (ORR ~20%)PDS0101: Versamune®-based immunotherapy generating HPV-specific CD8+ and CD4+ T-cells Study goals Group 1: Objective response rate (ORR) as first-line treatment in checkpoint inhibitor (CPI) naïve patientsGroup 2: ORR in patients who have failed checkpoint inhibitor therapy (CPI refractory) Timing Safety data confirmed and released Q4 2021Preliminary efficacy data anticipated Q1 2022 Trial Partner Confirmation that PDS0101 enhances the therapeutic benefit of checkpoint inhibitors could expand evaluation of Versamune®-based therapies in multiple cancer indications

12 Phase 2: PDS0101 + ChemoradiotherapyInvestigator-led trial evaluating the combination in patients with locally advanced cervical cancer (IMMUNOCERV) Indication Treatment of patients with locally advanced cervical cancer – Stages IB3-IVA Clinical Agents Chemoradiotherapy (CRT – Standard of Care): Cisplatin and radiation therapyPDS0101: Versamune®-based immunotherapy generating HPV-specific CD8+ and CD4+ T-cells Study goals Safety, rate of regression and local control in patients with primary tumor ≥5cm (n=35 patients) Timing Preliminary data anticipated Q2 2022 – Rate of complete response by PET-CT at 6 months and rate of tumor volume reduction by MRI at 30-40 days from start of treatment Trial Sponsor If successful, this study could support further investigation of Versamune®-based immunotherapies in combination with chemotherapy or CRT to treat multiple cancers

13 13 PDS0102: TARP Antigen Greater quantity and quality of Versamune®-induced CD8+ killer T-cells may result in ability to treat TARP positive prostate and breast cancers 1 Reference: Wood LV et al, Oncoimmunology, 2016, Vol. 5 (8)CFA – Complete Freund’s Adjuvant a highly potent immune activator not used in humans due to potentially lethal toxicity*Reference: Surveillance Research Program, National Cancer Institute SEER Assumes $150K for annual course of therapy; in line with current immunotherapy treatment PRE-CLINICAL OPTIMIZATION STUDIES1: TARP-Specific T-cell Induction after 2 injections of PDS0102 Announced license with NCI TARP antigens $40B TARP Total MarketOpportunity*

14 14 PDS0103: MUC1 AntigenGreater quantity and quality of Versamune®-induced CD8+ killer T-cells may result in ability to treat MUC1-positive cancers Induced a >10-fold number of polyfunctional (highly potent) MUC1 specific CD8+ T-cells Adjuvant = cytokine GMCSFReferences: J. Immunology, 2019 (202), 1215; Studies in TC-1 tumor model with other immunotherapies reported in: Vaccine 2009, January 14, 27 (3): 431; Science Translational Medicine 2016, 13 April, Vol 8 Issue 334; Vaccine 2009, September 25, 27 (42): 5906. $100B MUC1 Total Market Opportunity* *Reference: Surveillance Research Program, National Cancer Institute SEERAssumes $150K for annual course of therapy; in line with current immunotherapy treatment** Patient and value Asessments have not been adjusted to reflect MUC1-expression, which is currently unknown by tumor type

Projected Milestones Through 2022* *Based on current enrollment and forecast modeling as of January 2022. Subject to change. 4Q22 3Q22 2Q22 1Q22 4Q21 3Q21 2Q21 Preliminary efficacy data from advanced HPV-associated cancer trial (NCI) Interim data from HPV-associated cancer trial (NCI) Preliminary data from ImmunoCerv (MD Anderson) expected Preliminary data from VERSATILE-002 (KEYTRUDA® combo) expected Expected completion of HPV-associated cancer trial (NCI) PDS0101 15 PDS Biotech Funded Clinical Trials Partner Co-Funded Clinical Trials PDS0102 PDS0103 Planned initiation of Phase 1/2 clinical trial in TARP-related cancers Planned initiation of Phase 1/2 clinical trial in MUC1-related cancers

Infectimune™Infectious Disease Platform

PDS Biotech’s Infectimune™ Pipeline Developed in partnership with leaders in infectious disease 17 Reference: Data on file. *Consortium of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquimica. Funding provided by The Ministry of Science, Technology and Innovation of Brazil (“MCTI”).

PDS0202 Provided Effective Neutralization Against Multiple Strains of Flu Viruses in Preclinical Study AVERAGE HAI NEUTRALIZATION INEFFECTIVE ZONE 400 550 620 200 8 10 10 7 Average HAI Neutralization Titer Levels Induced by PDS0202 for Various Flu Strains vs Required Levels A / California / 07 / 2009 A / Michigan / 15 / 2014 A / Brisbane / 02 / 2018 (BR18) A / Guangdong-Maonan / SWL1536 / 2019 (GD19) H1N1 Strains H1 (+InfectimuneTM) H1 (Only) Average HAI Titers 40 18 Reference: Ross T. and Woodward J. et al. evaluation of the PDS0202 (Infectimune™ + COBRA) Universal flu formulation.

PDS0202 Provided Protection in Preclinical Study in Keeping Subjects Alive and Healthy Against Challenge with Flu Virus 19 100% 100% 100% 100% 0% 30% 0% Control Alive Healthy Alive Healthy Alive Healthy Alive Healthy High-Dose Flu Proteins (No Infectimune™) PDS0202 (High-Dose) PDS0202 (Low-Dose) % of Protection 0% Reference: Ross T. and Woodward J. et al. evaluation of the PDS0202 (Infectimune™ + COBRA) Universal flu formulation.

Universal FluAnnounced agreement for license with University of Georgia for universal flu antigensPreclinical work completePreclinical data to be submitted to peer reviewed journal for publication and future conferencesCOVIDAgreement with Farmacore extended through May 2022Scale up and manufacturing currently in process Infectimune™ Pipeline Highlights 20

PDS Biotech ManagementHistorical success in the development and commercialization of leading pharmaceutical products 21 Senior executive experience with management of strategy and execution at both large pharma and biotechsNotable drug development:Abelcet® (Liposome Company/ Elan)PEG-Intron® (Schering-Plough/ Merck) Frank Bedu-Addo, PhDChief Executive Officer Co-founder>35 years of drug development experience In-depth experience with biotech drug discovery, product development and manufacturing Gregory Conn, PhDChief Scientific Officer >30 years of translational clinical research experienceFormer Director of Clinical Research at National Cancer Institute Center for Cancer Research (Cancer Vaccine Branch) Lauren V. Wood, MDChief Medical Officer >20 years of financial and operational leadership roles for life sciences companiesFormer Chief Financial Officer of several publicly traded companies Matthew HillChief Financial Officer